Andrew B Nixon
Overview
Explore the profile of Andrew B Nixon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
112
Citations
1820
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
B-Lightning: using bait genes for marker gene hunting in single-cell data with complex heterogeneity
Shao Y, Gao Q, Wang L, Li D, Nixon A, Chan C, et al.
Brief Bioinform
. 2025 Feb;
26(1).
PMID: 39927857
In single-cell studies, cells can be characterized with multiple sources of heterogeneity (SOH) such as cell type, developmental stage, cell cycle phase, activation state, and so on. In some studies,...
2.
Alqaisi H, Cohn D, Chern J, Duska L, Jewell A, Corr B, et al.
Clin Cancer Res
. 2025 Jan;
PMID: 39836408
Purpose: Mesothelin (MSLN) is highly expressed in high grade serous/ endometrioid ovarian cancers (HGOC). Anetumab ravtansine (AR) is an antibody drug conjugate directed at MSLN antigen with a tubulin polymerization...
3.
Yazdani A, Lenz H, Pillonetto G, Mendez-Giraldez R, Yazdani A, Sanoff H, et al.
Commun Med (Lond)
. 2025 Jan;
5(1):9.
PMID: 39779996
Background: Gene signatures derived from transcriptomic-causal networks offer potential for tailoring clinical care in cancer treatment by identifying predictive and prognostic biomarkers. This study aimed to uncover such signatures in...
4.
Hwang J, Hwang J, Holl E, Holl E, Wu Y, Agarwal A, et al.
JCI Insight
. 2025 Jan;
10(4).
PMID: 39773530
Since multiple front-line immune checkpoint inhibitor-based (ICI-based) combinations are approved for metastatic renal cell carcinoma, biomarkers predicting for ICI responses are needed past clinical prognostication scores and transcriptome gene expression...
5.
Nixon A, Navarro F, Zhou K, Abbott C, McDaniel L, Howard L, et al.
Res Sq
. 2025 Jan;
PMID: 39764133
To explore whether ultra-sensitive circulating tumor DNA (ctDNA) profiling enables early prediction of treatment response and early detection of disease progression, we applied NeXT Personal, an ultra-sensitive bespoke tumor-informed liquid...
6.
Clarke J, Simon G, Mamdani H, Gu L, Herndon 2nd J, Stinchcombe T, et al.
Nat Commun
. 2025 Jan;
16(1):93.
PMID: 39747856
GT103 is a first-in-class, fully human, IgG3 monoclonal antibody targeting complement factor H that kills tumor cells and promotes anti-cancer immunity in preclinical models. We conducted a first-in-human phase 1b...
7.
Shao Y, Gao Q, Wang L, Li D, Nixon A, Chan C, et al.
bioRxiv
. 2024 Nov;
PMID: 39574750
In single-cell studies, cells can be characterized with multiple sources of heterogeneity such as cell type, developmental stage, cell cycle phase, activation state, and so on. In some studies, many...
8.
Liu Y, Li J, Lyu J, Howard L, Sibley A, Starr M, et al.
Cancer Epidemiol Biomarkers Prev
. 2024 Oct;
34(1):93-99.
PMID: 39400560
Background: Biomarker analyses are an integral part of cancer research. Despite the intense efforts to identify and characterize biomarkers in patients with cancer, little is known regarding the natural variation...
9.
Hall A, Brown S, Mettu N, Miller P, Smyth E, Nixon A
Am Soc Clin Oncol Educ Book
. 2024 Jun;
44(3):e433640.
PMID: 38888966
Gastroesophageal (GE) and pancreatobiliary (PB) cancers represent a significant clinical challenge. In this context, it is critical to understand the key molecular targets within these malignancies including how they are...
10.
Quintanilha J, Sibley A, Liu Y, Niedzwiecki D, Halabi S, Rogers L, et al.
BMC Genomics
. 2024 May;
25(1):473.
PMID: 38745123
Background: Herein, we report results from a genome-wide study conducted to identify protein quantitative trait loci (pQTL) for circulating angiogenic and inflammatory protein markers in patients with metastatic colorectal cancer...